$0.83
2.23% day before yesterday
Nasdaq, Jun 06, 10:00 pm CET
ISIN
NL0012661870
Symbol
IFRX
Sector
Industry

InflaRx N.V. Stock price

$0.83
-0.78 48.44% 1M
-1.79 68.32% 6M
-1.64 66.39% YTD
-0.78 48.44% 1Y
-5.75 87.38% 5Y
-14.16 94.46% 10Y
-14.16 94.46% 20Y
Nasdaq, Closing price Fri, Jun 06 2025
-0.02 2.23%
ISIN
NL0012661870
Symbol
IFRX
Sector
Industry

Key metrics

Market capitalization $55.73m
Enterprise Value $-18.85m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.34
EV/Sales (TTM) EV/Sales -125.68
P/S ratio (TTM) P/S ratio 371.52
P/B ratio (TTM) P/B ratio 0.65
Revenue growth (TTM) Revenue growth 36.36%
Revenue (TTM) Revenue $150.00k
EBIT (operating result TTM) EBIT $-61.30m
Free Cash Flow (TTM) Free Cash Flow $-54.68m
Cash position $75.43m
EPS (TTM) EPS $-0.80
P/E forward negative
P/S forward 129.74
EV/Sales forward negative
Short interest 1.56%
Show more

Is InflaRx N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

InflaRx N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a InflaRx N.V. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a InflaRx N.V. forecast:

Buy
88%
Hold
13%

Financial data from InflaRx N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.15 0.15
36% 36%
100%
- Direct Costs 3.56 3.56
314% 314%
2,373%
-0.18 -0.18
76% 76%
-120%
- Selling and Administrative Expenses 24 24
18% 18%
16,233%
- Research and Development Expense 40 40
4% 4%
26,787%
-61 -61
15% 15%
-40,507%
- Depreciation and Amortization 0.54 0.54
13% 13%
360%
EBIT (Operating Income) EBIT -61 -61
14% 14%
-40,869%
Net Profit -51 -51
8% 8%
-34,147%

In millions USD.

Don't miss a Thing! We will send you all news about InflaRx N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

InflaRx N.V. Stock News

Neutral
GlobeNewsWire
11 days ago
JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG), recommended that the trial be stopped...
Neutral
GlobeNewsWire
17 days ago
JENA, Germany, May 22, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in multiple investor conferences in June and July 2025.
Neutral
GlobeNewsWire
about one month ago
JENA, Germany, May 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the three months ended March 31, 2025, and provided a business update.
More InflaRx N.V. News

Company Profile

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

Head office Netherlands
CEO Niels Riedemann
Employees 74
Founded 2007
Website www.inflarx.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today